Marie O'Donnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marie O'Donnell has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alan Mackay
The Institute of Cancer Research 11 Division of Clinical Studies London, United Kingdom
4 shared publications - Alexander Lyulph Robert Lubbock
Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37212, United States of America
4 shared publications Antony C.P. Riddick
4 shared publications- Axel Bex
Department of Urology Royal Free London NHS Foundation Trust London UK
4 shared publications - Daniel Maurice Berney
Centre of Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute Queen Mary University of London London UK
4 shared publications - David J. Harrison
School of Medicine, University of St Andrews, North Haugh, St Andrews KY16 9TF, UK
4 shared publications
Latest Publications
- 31 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15113
High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia – Just a coincidence?
Introduction: Kidney transplant recipients (KTR) have a three‐to‐four‐fold increased risk of developing urothelial carcinoma (UC) compared to the general population. BK polyoma virus (BKV) infection is known to affect approximately 15% of KTR. In vitro models support a potential pathogenic role for BKV in the development of UC. We describe a series of UC in kidney transplant recipients.Methods: Electronic patient records were searched to identify KTR with UC who had undergone kidney only or simultaneous kidney and pancreas transplantation in a single UK center between 2009 and 2015. Where available, stored pathological samples were retrieved, re‐examined and stained for SV40 as a marker of BKV using standard staining protocols for kidney biopsy samples.Results: Fourteen KTR had developed UC post‐transplant. Of these, 10 KTR had a history of BKV infection post‐transplant. Six of these 10 KTR developed a rare micropapillary tumor subtype of UC which is typically only found in <1% of UC cases. All six micropapillary tumor samples stained positive for SV40, including samples from metastases. Three tumor samples were available from the four KTR with no history of BKV infection and were not micropapillary subtype and were negative for SV40. Three micropapillary tumors from immunocompetent patients were examined as controls and were negative for SV40.Conclusions: These findings would support a pathogenic role for BK virus in the development of rare micropapillary subtype urothelial tumors in the kidney transplant population.
- 31 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15113
High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia – Just a coincidence?
Introduction: Kidney transplant recipients (KTR) have a three‐to‐four‐fold increased risk of developing urothelial carcinoma (UC) compared to the general population. BK polyoma virus (BKV) infection is known to affect approximately 15% of KTR. In vitro models support a potential pathogenic role for BKV in the development of UC. We describe a series of UC in kidney transplant recipients.Methods: Electronic patient records were searched to identify KTR with UC who had undergone kidney only or simultaneous kidney and pancreas transplantation in a single UK center between 2009 and 2015. Where available, stored pathological samples were retrieved, re‐examined and stained for SV40 as a marker of BKV using standard staining protocols for kidney biopsy samples.Results: Fourteen KTR had developed UC post‐transplant. Of these, 10 KTR had a history of BKV infection post‐transplant. Six of these 10 KTR developed a rare micropapillary tumor subtype of UC which is typically only found in <1% of UC cases. All six micropapillary tumor samples stained positive for SV40, including samples from metastases. Three tumor samples were available from the four KTR with no history of BKV infection and were not micropapillary subtype and were negative for SV40. Three micropapillary tumors from immunocompetent patients were examined as controls and were negative for SV40.Conclusions: These findings would support a pathogenic role for BK virus in the development of rare micropapillary subtype urothelial tumors in the kidney transplant population.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-2, Supplementary Tables 1-2 from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
Supplementary Figures 1-2, Supplementary Tables 1-2. Fig. S1. Histogram showing lack of correlation between differential protein and RNA expression levels between sunitinib naive and treated patient samples; Figure S2: Dendrograms illustrating supervised Euclidean clustering of copy number variations (AC) and gene expression (D-F) for driver mutation genes (A+D), hypoxia genes (B+E) and stromal genes (C+F); Table S1: Validated antibodies used in RPPA experiments; Table S2: Differential expression of each protein in sunitinib naive and treated samples as evaluated by RPPA (1-8).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-2, Supplementary Tables 1-2 from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
Supplementary Figures 1-2, Supplementary Tables 1-2. Fig. S1. Histogram showing lack of correlation between differential protein and RNA expression levels between sunitinib naive and treated patient samples; Figure S2: Dendrograms illustrating supervised Euclidean clustering of copy number variations (AC) and gene expression (D-F) for driver mutation genes (A+D), hypoxia genes (B+E) and stromal genes (C+F); Table S1: Validated antibodies used in RPPA experiments; Table S2: Differential expression of each protein in sunitinib naive and treated samples as evaluated by RPPA (1-8).